| Literature DB >> 31167164 |
Gerald Raverot1,2,3, Alexandre Vasiljevic2,3,4, Emmanuel Jouanneau2,3,5, Hélène Lasolle1,2,3.
Abstract
Recent publications suggested that pasireotide could be a good therapeutic option in some dopamine-resistant or aggressive prolactinomas. We discussed the two published cases and describe another case of poorly differentiated plurihormonal PIT-1-positive adenoma with moderate SSTR2 expression and intense STTR5 expression successfully treated with PAS-LAR 40 mg/month.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31167164 DOI： 10.1530/EJE-19-0359
Source DB: PubMed Journal: Eur J Endocrinol ISSN： 0804-4643 Impact factor: 6.664